{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:20:45Z","timestamp":1788376845729,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The JAVELIN Bladder 100 phase 3 trial showed that avelumab first\u2010line maintenance\u2009+\u2009best supportive care significantly prolonged overall survival and progression\u2010free survival versus best supportive care alone in patients with advanced urothelial carcinoma who were progression\u2010free following first\u2010line platinum\u2010based chemotherapy. We report findings from J\u2010AVENUE (NCT05431777), a real\u2010world study of avelumab first\u2010line maintenance therapy in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical charts of patients with advanced urothelial carcinoma without disease progression following first\u2010line platinum\u2010based chemotherapy, who received avelumab maintenance between February and November 2021, were reviewed. Patients were followed until June 2022. The primary endpoint was patient characteristics; secondary endpoints included time to treatment failure and progression\u2010free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 79 patients analyzed, median age was 72\u2009years (range, 44\u201386). Primary tumor site was upper tract in 45.6% and bladder in 54.4%. The most common first\u2010line chemotherapy regimen was cisplatin\u2009+\u2009gemcitabine (63.3%). Median number of chemotherapy cycles received was four. Best response to chemotherapy was complete response in 10.1%, partial response in 58.2%, and stable disease in 31.6%. Median treatment\u2010free interval before avelumab was 4.9\u2009weeks. With avelumab first\u2010line maintenance therapy, the disease control rate was 58.2%, median time to treatment failure was 4.6\u2009months (95% CI, 3.3\u20136.4), and median progression\u2010free survival was 6.1\u2009months (95% CI, 3.6\u20139.7).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Findings from J\u2010AVENUE show the effectiveness of avelumab first\u2010line maintenance in patients with advanced urothelial carcinoma in Japan in clinical practice, with similar progression\u2010free survival to JAVELIN Bladder 100 and previous real\u2010world studies, supporting its use as a standard of care.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.15473","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T13:25:18Z","timestamp":1715261118000},"page":"859-867","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["J\u2010AVENUE: A retrospective, real\u2010world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first\u2010line maintenance therapy in Japan"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-6676","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Department of Urology St. Marianna University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Urology St. Marianna University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Urology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Uno","sequence":"additional","affiliation":[{"name":"Department of Urology Ogaki Municipal Hospital  Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroomi","family":"Nakatsu","sequence":"additional","affiliation":[{"name":"Department of Urology Asahi General Hospital  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyoe","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Hospital Organization Nagoya Medical Center  Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Urology Hamamatsu University School of Medicine  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Urology Kindai University Faculty of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Urology Showa University Fujigaoka Hospital  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Nishihara","sequence":"additional","affiliation":[{"name":"Department of Urology Kurume University School of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4135-6789","authenticated-orcid":false,"given":"Mizuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Akita University Hospital  Akita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology National Hospital Organization Kyushu Cancer Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-2464","authenticated-orcid":false,"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Nara Medical University Hospital  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-6258","authenticated-orcid":false,"given":"Takeshi","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Urology Kyoto University Graduate School of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research University of Toyama  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Medical Department Merck Biopharma Co., Ltd. (an affiliate of Merck KGaA)  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kajita","sequence":"additional","affiliation":[{"name":"Oncology Medical Affairs Merck Biopharma Co., Ltd. (an affiliate of Merck KGaA)  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-2816","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Kyoto University Graduate School of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research University of Toyama  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_14_3_1","unstructured":"National Cancer Center Japan.Project cancer statistics: projected cancer incidence in 2022.2022. Available from:https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_en.html. Accessed 19 Mar 2024."},{"key":"e_1_2_14_4_1","unstructured":"NCCN clinical practice guidelines in oncology: bladder cancer. v1.2024. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed 19 Mar 2024."},{"key":"e_1_2_14_5_1","unstructured":"National Cancer Institute.SEER Cancer Stat Facts: bladder cancer. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 19 Mar 2024."},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-021-00876-7"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)32244-4"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15014"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.08.016"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.10.013"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14281"},{"key":"e_1_2_14_12_1","unstructured":"Japanese Urological Association.Supplement to clinical practice guidelines for bladder cancer [2019 update].2021. Available from:https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/39_bladder_cancer_2019_rev2021_info.pdf. Accessed 19 Mar 2024."},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.026"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.02.002"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02067-8"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.471"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.469"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.06.008"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac186"},{"key":"e_1_2_14_25_1","unstructured":"KikuchiE NagataM SatoM KambeA OgiM EndoS et\u00a0al.Interim analysis of a post\u2010marketing surveillance (PMS) study of avelumab maintenance therapy in advanced or metastatic urothelial carcinoma (UC) in Japan. Presented at the 110th Annual Meeting of the Japanese Urological Association Kobe Japan; April 20\u201023. 2023:Abstract OP80\u201005."},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3173"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004563215608875"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:50:53Z","timestamp":1738911053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/iju.15473"],"URL":"https:\/\/doi.org\/10.1111\/iju.15473","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"2024-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}